The DOI matches its Crossref record, with a small difference in title or year; 40 of the 43 references it cites were found in a registry or an index, and 3 are not checked yet.
Combination Pharmacotherapy for Stopping Smoking: What Advantages Does it Offer?
Open accessAbstract
Globally, tobacco kills almost 5 million people around the world annually. Seven first-line pharmacotherapies are currently available and recommended by the United States Public Health Service (USPHS) clinical practice guideline for treating tobacco dependence, all of which have been proven to be effective for increasing tobacco abstinence rates when used as monotherapy. However, not all smokers are able to quit with single-drug therapy. Some smokers may benefit from combination therapy that includes the simultaneous use of different nicotine replacement therapies (NRTs) or medications with different mechanisms of action (e.g. NRT and bupropion). Combination therapy with different types of NRT may provide a therapeutic advantage by increasing serum nicotine concentrations, and combination therapy with different drugs may capitalize on synergy obtained from two different mechanisms of action. However, controversy exists regarding this approach. Available data suggests that combination therapy may increase abstinence rates compared with monotherapy. However, the cost effectiveness of this approach has not been clearly demonstrated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Following standard methods of economic evaluation, we will also perform parameter-specific sensitivity analyses in which individual parameters are varied singly and in combination, through plausible ranges to assess the relative impact different elements of the program have on overall cost-effectiveness.80–83”
From Evaluation of an integrated treatment to address smoking cessation and anxiety/depressive symptoms among people living with HIV: Study protocol for a randomized controlled trial (2021) · cites this paper as [81]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treating Tobacco Use and Dependence: 2008 Update: (566222009-001)
(2009) · PsycEXTRA Dataset · doi:10.1037/e566222009-001 · Cited by 3,046 · cited 6×
“The USPHS recommended the use of two types of behavioural counselling that have been consistently shown to increase smoking abstinence rates: (i) providing practical counselling such as problem solving and skills training; and (ii) providing support during a tobacco user’s direct contact with a clinician.([5]) In”
InfluentialTreating Tobacco Use and Dependence
(2008) · Pediatrics · doi:10.1542/peds.2008-1627 · Cited by 2,697
Nicotine replacement therapy for smoking cessation
Stead, L. F., Perera, R., Bullen, C., Mant, D., Hartmann-Boyce, J., Cahill, K., & Lancaster, T. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub4 · Cited by 2,464
Drugs of abuse: anatomy, pharmacology and function of reward pathways
Koob, G. F. (1992) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(92)90060-j · Cited by 2,070 · cited 1×
“with the release of the neurotransmitter dopamine in the mesolimbic system of the brain, which is involved in the positive reinforcement of addictive drugs.([3])”
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 2×
“For example, the combination of varenicline and bupropion SR combines the efficacy of varenicline with the ability of bupropion SR to reduce post-cessation weight gain.([11,12]) Combining different forms of NRT provides a stable baseline nicotine level from the SR NRT (i.”
Antidepressants for smoking cessation
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub5 · Cited by 1,352
A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation
Hurt, R. D., Sachs, D. P. L., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., Khayrallah, M. A., Schroeder, D. R., Glover, P. N., Sullivan, C. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710233371703 · Cited by 1,261
Self-citationNicotine receptor partial agonists for smoking cessation
Hey, K., Lancaster, T., & Bala, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103 · Cited by 861
Research works printed but not linked: 1
- Hughes, 2007, Cochrane Database Syst Rev, 1, CD000031
Cited by
The Past, Present, and Future of Nicotine Addiction Therapy
Prochaska, J. J., & Benowitz, N. L. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-033712 · Cited by 227
Lindson, N., Theodoulou, A., Ordóñez-Mena, J. M., Fanshawe, T. R., Sutton, A. J., Livingstone-Banks, J., Hajizadeh, A., Zhu, S., Aveyard, P., Freeman, S. C., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015226.pub2 · Cited by 177
“This could capitalise on the different mechanisms of action to combat tobacco addiction from multiple angles (Ebbert 2010).”
Mills, E. J., Wu, P., Lockhart, I., Thorlund, K., Puhan, M., & Ebbert, J. O. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.705016 · Cited by 163
Self-citationTreatment of nicotine addiction: present therapeutic options and pipeline developments
Polosa, R., & Benowitz, N. L. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.008 · Cited by 135
“Combinations of smoking-cessation medications appear to increase efficacy in smoking cessation compared to monotherapy [8,43].”
Chang, P.-H., Chiang, C.-H., Ho, W.-C., Wu, P.-Z., Tsai, J.-S., & Guo, F.-R. (2015) · BMC Public Health · doi:10.1186/s12889-015-2055-0 · Cited by 108
Metadata
- Authors
- Ebbert, J. O., Hays, J. T., & Hurt, R. D.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Ebbert, Jon O.
- Venue
- Drugs
- Published
- 2010-04
- Volume
- 70
- Issue
- 6
- Pages
- 643-650
- ISSN
- 0012-6667 (ISSN-L)
- PMC
- PMC3164516
- OpenAlex
- W2080075236
- Cited by
- 53
- References
- 40
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 6 · 2022: 5 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 2 · 2016: 2 · 2015: 6 · 2014: 4 · 2013: 4 · 2012: 4
- FWCI
- 0.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Pfizer
- National Institutes of Health
- U.S. Public Health Service
- National Cancer Institute (CA 138417Z, R01CA138417)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- smoking cessation, combination pharmacotherapy, nicotine replacement therapy, bupropion, tobacco dependence, nicotine abstinence, monotherapy, cost-effectiveness, drug synergy
- MeSH terms
- Animals, Drug Therapy, Combination, Humans, Nicotine, Smoking, Randomized Controlled Trials as Topic, Smoking Cessation, Bupropion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination Pharmacotherapy for Stopping Smoking: What Advantages Does it Offer? https://app.cochat.ai/papers/10.2165/11536100-000000000-00000
- The paper
- Ebbert, J. O., Hays, J. T., & Hurt, R. D. (2010). Combination Pharmacotherapy for Stopping Smoking: What Advantages Does it Offer? Drugs. https://doi.org/10.2165/11536100-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.